| Prader-Willi Syndrome
Norditropin vs Vykat
Side-by-side clinical, coverage, and cost comparison for prader-willi syndrome.Deep comparison between: Norditropin vs Vykat Xr with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsVykat Xr has a higher rate of injection site reactions vs Norditropin based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Vykat Xr but not Norditropin, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Norditropin
Vykat Xr
At A Glance
SC injection
Daily
Recombinant human growth hormone
Oral
Daily
Insulin secretion inhibitor
Indications
- Noonan Syndrome
- Turner Syndrome
- Prader-Willi Syndrome
- Prader-Willi Syndrome
Dosing
Pediatric GHD 0.17-0.24 mg/kg/week SC, divided into equal doses given 6 or 7 days per week.
Noonan Syndrome Up to 0.46 mg/kg/week SC, divided into equal doses given 6 or 7 days per week.
Turner Syndrome, SGA, ISS Up to 0.47 mg/kg/week SC, divided into equal doses given 6 or 7 days per week.
Prader-Willi Syndrome 0.24 mg/kg/week SC, divided into equal doses given 6 or 7 days per week.
Adult GHD (non-weight-based) Initiate at approximately 0.2 mg/day SC (range 0.15-0.3 mg/day); increase every 1-2 months by 0.1-0.2 mg/day based on clinical response and IGF-1 concentrations.
Adult GHD (weight-based) Initiate at 0.004 mg/kg/day SC; increase to a maximum of 0.016 mg/kg/day; not recommended for obese patients.
Prader-Willi Syndrome Administer once daily orally; starting dosage 25-150 mg based on body weight with titration every 2 weeks; target maintenance dose 75-525 mg/day; maximum 5.8 mg/kg/day or 525 mg/day; swallow tablets whole without splitting, crushing, or chewing.
Contraindications
- Acute critical illness after open heart surgery, abdominal surgery, multiple accidental trauma, or acute respiratory failure
- Pediatric patients with Prader-Willi syndrome who are severely obese, have a history of upper airway obstruction or sleep apnea, or have severe respiratory impairment
- Active malignancy
- Hypersensitivity to somatropin or any excipient of NORDITROPIN
- Active proliferative or severe non-proliferative diabetic retinopathy
- Pediatric patients with closed epiphyses
- Known hypersensitivity to diazoxide, other components of VYKAT XR, or to thiazides
Adverse Reactions
Most common (>=5%, adult onset GHD) Peripheral edema, edema, arthralgia, leg edema, myalgia, non-viral infection, paraesthesia, skeletal pain, headache, bronchitis, flu-like symptoms, hypertension, gastroenteritis, increased sweating, abnormal glucose tolerance, laryngitis, type 2 diabetes mellitus
Serious Increased mortality in acute critical illness, sudden death in pediatric PWS patients, neoplasms, intracranial hypertension, severe hypersensitivity reactions, fluid retention, slipped capital femoral epiphysis, pancreatitis
Postmarketing Anaphylactic reactions, angioedema, increase in cutaneous nevi, hypothyroidism, gynecomastia, hyperglycemia, osteonecrosis, increased blood alkaline phosphatase, decreased serum T4, pancreatitis, leukemia
Most common (>=10%) Hypertrichosis, edema, hyperglycemia, rash
Serious Hyperglycemia, fluid overload, pulmonary edema, diabetic ketoacidosis, aggression, diabetes mellitus, peripheral edema, lower respiratory tract infection, papular rash (adverse reactions leading to discontinuation)
Pharmacology
Recombinant human growth hormone (somatropin) binds to dimeric GH receptors on target tissue cell membranes, triggering intracellular signal transduction and induction of GH-dependent proteins including IGF-1, IGFBP-3, and acid-labile subunit, which stimulate chondrocyte differentiation and proliferation, hepatic glucose output, protein synthesis, lipolysis, and skeletal linear growth via effects on epiphyses of long bones.
Diazoxide choline is hydrolyzed to diazoxide prior to absorption; diazoxide increases blood glucose primarily by inhibiting insulin release from the pancreas, though the exact mechanism for treating hyperphagia in Prader-Willi syndrome is unknown.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Norditropin
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (4/12) · Qty limit (9/12)
Vykat Xr
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (0/12) · Qty limit (9/12)
UnitedHealthcare
Norditropin
- Covered on 4 commercial plans
- PA (5/8) · Step Therapy (1/8) · Qty limit (4/8)
Vykat Xr
- Covered on 4 commercial plans
- PA (5/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Norditropin
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (2/3) · Qty limit (0/3)
Vykat Xr
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Norditropin.
No savings programs available for Vykat Xr.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
NorditropinView full Norditropin profile
Vykat XrView full Vykat Xr profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.